SERUM SIALYL TN AS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS IN PATIENTS WITH EPITHELIAL OVARIAN-CANCER

被引:141
作者
KOBAYASHI, H
TERAO, T
KAWASHIMA, Y
机构
[1] Dept. of Obstetrics/Gynecology, Hamamatsu University, School of Medicine, Hamamatsu, Shizuoka 431-31
关键词
D O I
10.1200/JCO.1992.10.1.95
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Monoclonal antibody (moAB) TKH-2 directed to the tumor-associated O-linked sialyl 2-6-α-N-acetylgalactosaminyl (sialyl Tn; STN) epitope was generated by immunization with ovine submaxillary mucin (Kjeldsen et al, Cancer Res 48:2214-2220, 1988). We investigated whether circulating serum levels of STN antigen might influence the prognosis of patients with ovarian cancer. Patients and Methods: Serum samples were obtained from 126 healthy nonpregnant women, 157 patients with benign gynecologic disease, and 89 patients with histologically proven epithelial ovarian cancer. Circulating serum STN-antigen concentrations (U/mL) were determined by a competitive radioimmunoassay kit (Otsuka Assay Laboratories, Tokushima, Japan) in a one- step procedure. Results: Serum antigen levels were elevated in 48.3% of the patients. The levels of STN antigen were significantly higher in the sera of patients with cancer when compared with levels in benign and healthy controls (P < .05). The 5-year survival rate for patients with STN-negative (serum STN levels < 50.0 U/mL) versus STN-positive (≥ 50 U/mL) tumors was 76.9% versus 10.8%, respectively (P < .05). The progression-free interval (PFI) at 5 years was 51.9% versus 5.4%, respectively (P < .05). The overall survival probability and PFI were worse in patients with STN-positive sera. Multivariate regression analysis revealed that stage, residual tumor size, positive STN, performance status, and histologic grade were the five important variables for predicting overall survival. Conclusion: We conclude that a positive STN-antigen level in sera is an independent predictor of poor prognosis in ovarian cancer.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 29 条
[1]  
BARBIERI RL, 1986, FERTIL STERIL, V45, P630
[2]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[3]   REACTIVITY OF A MONOCLONAL-ANTIBODY WITH HUMAN OVARIAN-CARCINOMA [J].
BAST, RC ;
FEENEY, M ;
LAZARUS, H ;
NADLER, LM ;
COLVIN, RB ;
KNAPP, RC .
JOURNAL OF CLINICAL INVESTIGATION, 1981, 68 (05) :1331-1337
[4]  
DAVIS HM, 1986, CANCER RES, V46, P6143
[5]  
DELVILLANO BC, 1983, CLIN CHEM, V29, P549
[6]  
FUKUSHI Y, 1985, CANCER RES, V45, P3711
[7]  
GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203
[8]  
HAKOMORI S, 1985, CANCER RES, V45, P2405
[9]  
HAMAJIMA N, 1989, Journal of Japan Society for Cancer Therapy, V24, P579
[10]   MONOCLONAL-ANTIBODY DETECTION OF A CIRCULATING TUMOR-ASSOCIATED ANTIGEN .1. PRESENCE OF ANTIGEN IN SERA OF PATIENTS WITH COLORECTAL, GASTRIC, AND PANCREATIC-CARCINOMA [J].
HERLYN, M ;
SEARS, HF ;
STEPLEWSKI, Z ;
KOPROWSKI, H .
JOURNAL OF CLINICAL IMMUNOLOGY, 1982, 2 (02) :135-140